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Abstract 
Objective: The goal of this research is to demonstrate that well-regulated glycemia is beneficial 
to patient outcome, regardless of how it is achieved. 
Methods: This analysis used data from 1701 patients from two, independent studies. Glycemic 
outcome were measured using cumulative Time In Band (cTIB), calculated for three glycemic 
bands and for threshold values of t = 0.5, 0.6, 0.7 and 0.8. For each day of ICU stay, patients 
were classified by cTIB, threshold and hospital mortality, and odds of living (OL) and odds 
ratio (OR) were calculated.  
Results: OL given cTIB ≥ t is higher than OL given cTIB < t for all values of t, every day, for 
all three glycemic bands studied. The difference between the odds clearly increased over ICU 
stay for t > 0.6. Higher cTIB thresholds resulted in larger increases to OR over time and were 
particularly significant for the 4.0-7.0 mmol/L glycemic band.  
Conclusion: Increased cTIB was associated with higher OL. These results suggest that 
effective GC positively influences patient outcome, regardless of how the glycemic regulation 
is achieved. BG < 7.0 mmol/L is associated with a measurable increase in the odds of survival, 
if hypoglycemia is avoided.  
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1 Introduction 
High and variable blood glucose (BG) levels have been associated with increased mortality in 
critically ill patients 1-5. Glycemic control (GC) has significantly reduced mortality 6-8, but many 
studies have failed to reproduce these results 9-12. These contradictory results have engendered 
skepticism towards GC in the critically ill patients 13-16.  
There are three main difficulties with GC. First, a high risk of hypoglycemia 4, 17-19, which is 
independently associated with poor outcome 4, 19, where only one study reduced hypoglycemia 
during GC 8. Second, all GC protocols specify a limit or target band with the aim of reducing 
persistent hyperglycemia, to best ensure improved patient outcome. However, there is currently 
no expert consensus about a best GC target band 13, 20, 21. Third, metrics of performance for 
glycemic control can typically only be evaluated at the end of the patient stay in the intensive 
care unit (ICU) 22. However, it is important that clinicians are able to assess GC performance 
with respect to potential outcome at any time during stay to inform clinical decision-making. 
The goal of this research is to demonstrate that well-regulated glycemia is beneficial to patient 
outcome, regardless of how it is achieved. Key to this demonstration is a metric that 
continuously and adequately captures the concept of ‘well regulated.’ We strongly agree with 
MacKenzie 23 that both glycemic level and variability are essential components of well-
regulated glycemia. Cumulative time in band (cTIB) is a simple metric that fulfills these criteria 
and enables us to investigate the impact of glycemia on patient outcome in terms of total 
exposure to pre-defined glycemic bands. Thus, we reanalyze data from two different glycemic 
control trials and use an odds ratio based on cTIB and mortality to show that certain glycemic 
bands are better than others.  
2 Subjects and Methods 
2.1 Patients 
This study used glycemic data from 1701 patients from two, independent studies: 
1. SPRINT: Prospective SPRINT and retrospective pre-SPRINT cohorts were included in this 
study. These patients were admitted to Christchurch Hospital ICU between January 2003 
and May 2007 (N=784) 8, 24.  
2. Glucontrol: A randomized multi-center study, admitted to ICUs from 3 November 2004 to 
30 May 2006 (N=917) 9.  
These two datasets represent very different ICU cohorts with conflicting results in GC trials. 
SPRINT reduced organ failure, mortality and hypoglycemia compared to the retrospective 
cohort 8, 24. The Glucontrol trial showed no benefit from GC to a low target compared to a 
higher target and, as is often the case, reported increased hypoglycemia for the low target cohort 
9. Local protocols had measurment frequency within the 1-4 hourly range for all periods where 
patients were glycaemically controlled. Patient data are summarized in Table 1 and the number 
of patients remaining in the ICU at each day are shown in Figure 1. 
Table 1. Patient data shown as median [interquartile range] where appropriate. 
 
SPRINT  
study 
Glucontrol 
study 
All 
Number of patients 784 917 1701 
Percentage of males 61.2 62.9 62.1 
Age of patients 65.0 [52.0 - 74.0] 65.2 [51.5 - 74.1] 65.0 [51.6 - 74.0] 
APACHE 2 score 18.0 [15.0 - 24.0] 15.0 [11.0 - 21.0] 17.0 [13.0 - 23.0] 
Cohort BG (mmol/L) 6.2 [5.3 - 7.4] 6.9 [5.8 - 8.4] 6.6 [5.6 - 8.1] 
Per-patient median BG (mmol/l) 6.3 [5.6 - 7.5] 6.9 [6.1 - 8.2] 6.6 [5.8 - 7.9] 
% BG in 4.0-7.0 mmol/L 66.8 50.0 56.6 
Number of patients with BG < 2.2 
mmol/L 
36 54 90 
 Figure 1. Patients remaining in the ICU at each day. 
 
2.2 Analysis 
Glycemic outcome and performance were measured using cumulative Time In Band (cTIB), 
calculated for each patient for each day of stay. cTIB is the time spent within the pre-defined 
glycemic band as a proportion of the total time up to and including the day under consideration 
24. Further, each patient day was classified into a category based on whether their cTIB value 
exceeded a pre-defined threshold, t, permitting a simple analysis of cohort behavior. Thus, for 
a given threshold, t, cTIB accounts simultaneously for both BG level and variability, where 
variability within the band is tolerated and more time (higher t) within a band of defined width 
limits overall variability.  
To enable comparison, cTIB must be calculated from data with a constant measurement 
frequency. Clinical measurements from this retrospective data were not necessarily hourly, thus 
interpolated data were used in the calculation of cTIB when required. Across the entire cohort, 
the average duration between measurements was 2.5 hours. The analyses were performed for 
the first 14 days of glycemic monitoring, which typically commenced shortly after admission 
to the ICU. After 14 days, less that 15% of patients remained in the ICU.  
For a specific day d, cTIB is calculated using Equation (1), where (𝐵𝐺𝑑𝑎𝑦(𝑖) ∈ 𝑏𝑎𝑛𝑑) are the 
hourly interpolated BG levels included in the defined glycaemic band. 
 𝑐𝑇𝐼𝐵(𝑑) =
∑ (𝐵𝐺𝑑𝑎𝑦(𝑖) ∈ 𝑏𝑎𝑛𝑑)
𝑑
𝑖=1
∑ 24 ∗ 𝑖𝑑𝑖=1
 (1) 
In this study, cTIB was calculated for the 4.0-7.0 mmol/L, 5.0-8.0 mmol/L and 4.0-8.0 mmol/L 
glycemic bands. These bands represent two different intermediate glycemic levels with similar 
tolerated variability  (4.0-7.0 mmol/L and 5.0-8.0 mmol/L), and a wider band allowing more 
variability (4.0-8.0 mmol/L). These specific ranges were considered as they could reasonably 
be used as target bands for GC given current thinking 2, 25-27. Threshold values of t = 0.5, 0.6, 
0.7 and 0.8 were considered, where a higher threshold value indicates less tolerance of 
dysglycemia. These thresholds were used as they represent achievable levels of quality control, 
and the value t = 0.5 has been used previously to separate quality of control in association with 
clinical outcome24. 
For each day during the first 14 days of ICU stay, patients were classified by cTIB, threshold 
and outcome hospital mortality, yielding a 2x2 contingency matrix for each day (2). Crucially, 
this classification was performed independent of the intention-to-treat groups and thus enables 
the analysis of the association between glycemic level and mortality, regardless of whether the 
glycemic control was achieved by protocol, natural regulation or a combination.  
 
     L       D 
𝑐𝑇𝐼𝐵 ≥ 𝑡
𝑐𝑇𝐼𝐵 < 𝑡
 [
𝑁1 𝑁2
𝑁3 𝑁4
] 
(2) 
The odds of living (OL) given cTIB ≥ 𝑡 are defined as 𝑁1/𝑁2 and similarly for cTIB < 𝑡. Where 
Nx represents the number of patients that lived (L) or died (D) for each cTIB state. The odds 
ratio (OR), defined as the ratio of OL given cTIB ≥ 𝑡 to OL given cTIB < 𝑡: 
 OR =
𝑁1𝑁4
𝑁2𝑁3
 (3) 
Equation (4) describes the 95% confidence interval about OR 28: 
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For each day of ICU stay, OL and OR, with 95% confidence interval (CI), were calculated for 
the cohort. The association between glycemic performance (defined by the cTIB metric) and 
mortality outcome was tested using the Chi-squared test with the contingency matrix (2).  
3 Results 
Figure 2 shows the odds of living, by day for the combined cohort for each band and threshold 
(t). The asterisks indicate a statistically significant (p < 0.05, chi-squared test) association 
between cTIB ≥ t and mortality. Figure 3 similarly presents the evolution of OR over time with 
associated confidence intervals.  
 
Figure 2. Cohort odds of living for each glycemic band and threshold value during ICU stay. 
 
Figure 3. Cohort odds ratio for each band and threshold during ICU stay. 
 
When considering separately results for patients who experienced hypoglycemia (at least on 
BG < 2.2 mmol/L) and patients who did not (Supplemental file), results showed that for patients 
experiencing severe hypoglycemia the odds ratio is not different than 1.0. Those patients who 
did not experience severe hypoglycemia had very similar odds ratio values compared to the 
entire cohort, with differences being clinically and numerically very small to negligible as a 
result of the relatively lower numbers of severe hypoglycemic events over the large cohort. 
Thus, compared to the entire cohort as a whole, severe hypoglycemia significantly reduces odds 
ratios, but avoiding it did not significantly improve them. The Supplemental file repeats Figure 
3 for comparison for both the severe hypoglycemia cohort and the cohort who did not 
experience hypoglycemia
4 Discussion 
Two key factors influence GC in the ICU. First, is the physiological question: Does adequately 
regulated BG benefit patients? The second, and arguably more difficult, factor is the actual 
implementation of successful, accurate GC in a busy ICU environment. Van den Berghe et al. 
7, 27 separated these factors by using a specialist nursing team and focused on the physiological 
question, demonstrating the benefit of GC on patient outcome. A number of studies added 
weight to this finding by pinning down the pathophysiological mechanisms and pathways 
behind glucose toxicity 29-33. This study is unique in that it analyses the combined results from 
two studies, in normal clinical settings, based on glycemic level, rather than the treatment 
group. It thus effectively separates physiology from implementation. 
It is immediately clear from Figure 2 that OL given cTIB ≥ 𝑡 is higher than OL given cTIB < 𝑡 
for all values of 𝑡, every day, for all three glycemic bands studied. Furthermore, Figure 3 shows 
that the difference between the odds clearly increased over ICU stay for t = 0.7 and 0.8. In each 
case, the odds ratio tended to increase over ICU stay until Day 11. Higher cTIB thresholds 
resulted in larger increases to OR over time and were particularly significant for the 4.0-
7.0 mmol/L glycemic band.  
In particular, in this study, the three bands and various thresholds, t, used test different 
acceptable levels and variability of glycemia. The comparison of the 4.0-7.0 and 5.0-8.0 
mmol/L bands for a given value of t effectively compare the average glycemic level achieved. 
Comparison to the wider 4.0-8.0 mmol/L band assesses the impact of increased potential 
variability allowed by a wider band width. In Figure 3, the results show advantage for lesser 
variability and a lower glycemic level, where increasing strictness with rising threshold, t, 
yields better results across all bands. 
This study’s results clearly demonstrate a strong association between accurate glycemic control 
and mortality, regardless of how the glycemic regulation came about. Regulated glycemia was 
considered equally good whether it was due to a tight GC protocol, endogenous regulation, or 
a combination. In particular, more time spent within the 4.0-7.0 mmol/L glycemic band was 
associated with higher odds of survival compared to the higher and wider bands. Moreover, 
patients who did not experience severe hypoglycemia during their ICU stay had slightly higher 
odds ratio values than the entire cohort. Those had at least one BG < 2.2 mmol/L had odds 
ratios indistinguishable from 1.0, although this cohort was relatively quite small. This finding 
matches results in the literature suggesting the negative effects of severe hypoglycemia. In 
concert with Figure 3, they suggest that safe, effective control in a 4.0 - 7.0 mmol/L range, as 
defined here using cTIB, is associated with a measurable increase in the odds of survival, if 
hypoglycemia is avoided. 
A possible reason why randomized controlled GC trials yielded conflicting results is that they 
targeted glycemic level with no means to directly manage variability. These results thus suggest 
that protocols that directly minimize variability within a specific target band (i.e. level and 
variability) should be prospectively tested to ascertain whether there is a causal relationship 
with outcome. Hence, this result is not inconsistent with the latest results of the NICE-SUGAR 
study 10, and other recent reports. Future studies could also examine the ability to achieve given 
thresholds for specific sub-cohorts based on diagnosis, organ failure, or other severity score, 
over time. 
An important aspect of this study was the use of the cumulative time in band metric. This metric 
captures both the level and variability of glycemia, as well as relative exposure to dysglycemia. 
The cTIB metric was shown to be strongly associated with patient outcome, particularly after 
3 days of ICU stay, as indicated by the lower limits of the 95% confidence intervals of Figure 
3. Chase et al. and Van den Berghe et al. 8, 27 also reported reduced mortality after 3 or more 
days of glycemic control. Therefore, cTIB provides a simple, yet useful metric for clinicians 
and investigators to evaluate the evolution of glycemic control in patients in real-time.  
The choices of glycemic ranges investigated in this study were not arbitrary. Several studies 
have shown that targeting BG ≤ 8.1 mmol/l is beneficial 2, 25. However, fear of hypoglycemia 
has driven suggested target ranges higher 21. Thus, the ranges investigated in this study were 
intermediate and achievable, provided the metabolic variability leading to hypo- and hyper- 
glycemia can be managed 34. 
Clinically, in consideration of the pathophysiological basis of increasing cellular dysfunction 
with dysglycemia, this cTIB metric captures glycemic variability and glycemic level in 
combination with the length of exposure to these effects. This metric can readily be targeted by 
control protocols and evaluated regularly (daily or more frequently) in real-time at the patient’s 
bedside. 
It is also interesting to note that by Day 11 or 12, the odds ratio starts deceasing in some cases 
in Figure 3. However, by this point only ~20% of the patients are remaining (Figure 1) who are 
likely very critically ill. Thus, these results may be explained by the fact that by that time only 
the very ill, longer staying patients are left. 
The limitations of this study should be acknowledged. First, BG measurement frequency varied 
between patients and centers. To use the cTIB metric, the data needed to have a constant and 
consistent frequency, thus BG measurements were interpolated to provide one value per hour. 
As the cTIB metric is a cumulative method for quantifying glycemic behavior over time, we 
feel that interpolation is justified, as it captures the average trend of the BG between the 
measurements.  
Second, this study was performed on retrospective data, thus we can only note the association 
between well-regulated glycemia and outcome mortality and cannot prove causation. However, 
others 29-33 have determined pathophysiological pathways between hyperglycemia, glycemic 
variability and negative outcomes. So, although well-regulated glycemia may be a symptom of 
more healthy patients, rather than a cause, we feel that the evidence from numerous 
pathophysiological and clinical studies suggests that the association seen in this study results 
from an underlying causative pathway, which should be further investigated prospectively. 
 
Third, the analysis groups all cohorts and patients together. It thus considers the glycemic 
outcomes of a large, heterogeneous cohort made of different types of patients who were treated 
differently in terms of insulin. The glycemic outcomes were thus variable, and due to the 
different quality of control protocols used, did not necessarily match expectations, where less 
ill cohorts by APACHE score had sometimes higher glycemic levels and variability. As a result, 
the study cannot clearly define or delineate for which sub-cohort, such as surgical patients in 
[7] or the medical ICU patients of [8], the results are better or worse.  
 
However, the main objective of this study was to demonstrate an association between level and 
variability of glycemic control achieved, regardless of how that outcome was achieved or by 
what protocol, and patient outcome.  It was not intended to link the ability to achieve a glycemic 
outcome and the level of illness which remains to be defined, although the SPRINT controlled 
group of [8] did consistently achieve control over such a broad cohort as seen in [24]. Hence, 
as a final limitation, the results presented thus offer a stepping stone for greater delineation and 
refinement with larger cohorts in additional studies. 
 
 
5 Conclusions 
Increased cumulative time in an intermediate glycemic band was associated with higher odds 
of living. These results suggest that effective GC positively influences patient outcome, 
regardless of how the glycemic regulation is achieved. There were significant differences in the 
glycemic bands studied with a 4.0-7.0 mmol/L band showing improved results over a similar 
width band between 5.0-8.0 mmol/L, indicating that BG lower than 7.0 mmol/L is associated 
with a measurable increase in the odds of survival, if hypoglycemia is avoided. Hence, these 
results demonstrate an association between the level and tightness of control, regardless of how 
it is achieved, and outcome, while offering a foundation to further studies to clarify the link 
between severity of illness and ability to achieve a glycemic level and variability. 
 
The cTIB metric can be readily calculated in real-time and used to assess GC in progress, as 
well as providing a useful, simple target for GC studies. The single metric encapsulates the 
need to achieve control of both level and variability to minimize cellular dysfunction, as well 
as linking the level of achievement to patient outcome over each day of stay. 
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Figure captions 
Figure 1. Patients remaining in the ICU at each day. 
Figure 2. Cohort odds of living for each glycemic band and threshold value during ICU stay. 
Figure 3. Cohort odds ratio for each band and threshold during ICU stay. 
  
Table captions 
Table 1. Patient data shown as median [interquartile range] where appropriate. 
 
 
